Loading
A phase 3 trial of Pemetrexed, Carboplatin, Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by Innovent Biologics (Suzhou) Co. Ltd., active and no longer recruiting.
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer is a phase 3 interventional study registered as NCT05116462 by Innovent Biologics (Suzhou) Co. Ltd., with 506 participants enrolled, started 2024-03-15 and due to reach its primary completion in 2026-09-30. Interventions recorded: Pemetrexed, Carboplatin, Paclitaxel, Sintilimab, Cisplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Innovent Biologics, Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Cisplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Cisplatin, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin.